3'-Azido-2',3'-dideoxy-5-methylcytidine (AzddMeC) has been shown to have potent activity against human immunodeficiency virus (HIV) in vitro. The purpose of this study was to characterize the pharmacokinetics of AzddMeC in rats. AzddMeC was administered intravenously at doses of 10, 50 and 100mg kg-\ Plasma and urine AzddMeC concentrations were determined by HPLC. Pharmacokinetic parameters were generated by area/moment analysis. Plasma AzddMeC concentrations after 10mg kg-1 were too low to accurately calculate pharmacokinetic parameters. Following 50 and 100mg kg-1 AzddMeC, plasma drug concentrations declined rapidly with a terminal half-life of approximately 2.5 h. No statistically significant differences were noted in pharmacokinetic parameters between the two higher doses.
Introduction
3'-Azido-2',3'-dideoxy-5-methylcytidine (AzddMeC, CS-92) is a nucleoside analogue with structural similarities to both 3'-azido-3'-deoxythymidine (AZT) and 2',3 'dideoxycytidine (ddC) . Figure 1 shows the chemical structure of AzddMeC compared with AZT and ddC. The physical-chemical characteristics of AzddMeC show similarities, and differences, to AZT and ddC. Both AzddMeC and ddC are weakly basic compounds with pka values of 4-5, whereas AZT is a weak acid with a pka value of 9.7. All three nucleosides would be expected to be unionized at physiological pHs. The octanol to water partition coefficients, an indicator of lipid solubility, of AzddMeC, AZT and ddC are 0.40, 1.1 and 0.04, respectively. Thus, the lipophilicity of AzddMeC is twofold lower than that of AZT, but 10-fold greater than that of ddC.
AzddMeC has been shown to be a potent inhibitor of human immunodeficiency virus (HIV-1) in vitro. In primary lymphocytes infected with HIV, AzddMeC had a median effective concentration of 5.1 fLM with no apparent toxicity at concentrations up to 100 fLM (Lin et al., 1988) . Further studies in human peripheral blood mononuclear cells infected with HIV-1 demonstrated a median effective concentration in the range of 0.081-0.22 fLM, while the toxic concentration was greater than 200 fLM (Schinazi et aI., 1990) . Herdewijn et al. (1988) reported that AzddMeC had a median effective concentration of 1.8 fLM with no toxicity up to 1mMin MT-4 cells infected with HIV-1. Thus, AzddMeC has a selective antiviral effect in various cells and has potential for the treatment of acquired immunodeficiency syndrome (AIDS). The purpose of this report was to characterize the preclinical pharmacokinetics of AzddMeC in rats.
Results
Chromatograms of extracts of blank rat plasma, plasma spiked with AzddMeC, AZT and internal standard and a plasma sample taken after intravenous administration of 100mg kg-1 of AzddMeC in a rat are shown in Fig. 2 . No endogenous interfering peaks were visible in blank plasma. Retention times for AzddMeC and internal standard were 2.6 and 8.3 min, respectively. AZT could also be quantified with this system with a retention time of 4.1 min. Extraction recovery of AzddMeC and internal standard 
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The purpose of this study was to characterize the preclinical pharmacokinetics of AzddMeC in rats. Relatively high doses were administered to describe fully the disposition of AzddMeC. Indeed, doses of AzddMeC exceeding 10 mg kg-1 were necessary to completely characterize the disposition pattern of the nucleoside. Similar doses have been employed to investigate the pharmacokinetics of other nucleosides in laboratory animals (Kelleyet aI., 1987; Ray and Mason, 1988; Patel et aI., 1989; Ibrahim and Boudinot, 1989a) .
Approximately 55% of an intravenously administered dose of AzddMeC was excreted unchanged in urine. A glucuronide metabolite of AzddMeC was not detected in urine. AzddMeC could potentially be deaminated by 2' ,deoxycytidine deaminase to AZT; however, no AZTwas detected in plasma or urine samples after AzddMeC administration to rats. Steady-state volume of distribution was also independent of dose.
was 85%. The assay was linear in the range of 0.1 to 100 f.Lg rnl", and the lower limit of quantification was 0.1 f.Lg rnl" (10ng). The intra-and inter-day coefficients of variation for the assay were less than 10% at all drug concentrations. Representative plasma AzddMeC concentration versus time curves after intravenous doses of 10, 50 and 100 mg kg-1 are depicted in Fig. 3 . Following 50 and 100mg kg-1 doses, plasma AzddMeC concentrations declined in a triexponential pattern with a terminal disposition half-life of approximately 2.5 h. However, a biexponential decline in plasma AzddMeC concentrations with a terminal halflife of approximately 0.5 h was observed after 1Omg kg-1 . The biphasic decline of plasma nucleoside concentrations after the low dose paralleled the first two phases seen after the higher doses. A longer terminal half-life was not observed after 10mg kg-1 AzddMeC, probably because AzddMeC concentrations constituting the terminal phase fell below the limit of quantification of the assay. That the disposition of AzddMeC after 10mg kg-1 followed a triexponential pattern was supported by urinary excretion rate versus time curves. Indeed, calculation of the terminal disposition half-life based on two to three urinary excretion rate intervals yielded half-life values of 2.73 ± 2.47h (mean ± SD), 2.62 ± 1.17h and 2.13 ± 0.51h after 10, 50 and 100 mg kg-1 doses, respectively. There were no statistically significant differences between half-life values generated from urinary excretion rates and dose. In addition, the half-life values calculated from urinary excretion rates after 50 and 100mg kg-1 AzddMeC were virtually identical to those obtained from plasma nucleoside concentrations (Tables 1 and 2) .
Pharmacokinetic parameters of AzddMeC following intravenous administration of 50 and 100 mg kg-1 to rats are presented in Tables 1 and 2, respectively. Since the disposition profile of AzddMeC was incomplete after administration of 10 mg kg-1 due to limitations in assay sensitivity, pharmacokinetic parameters for this dose are not reported. There were no statistically significant differences between any of the clearance values and dose. Fig. 3 . Plasma concentrations of AzddMeG after 10 (0), 50 (0) and 100 (6) mg kg-1 intravenous doses to rats.
The pharmacokinetics of AzddMeC were independent of dose over a dosage range of 50 to 100mg kg-1 . AzddMeC appeared to be widely distributed throughout the body since its steady-state volume of distribution was greater than total body water (0.701 kg-1 ) of the rat (Gerlowski and Jain, 1983) . In addition, the AzddMeC plasma concentration versus time profiles showed a rapid, but marked, distribution of the nucleoside.
AzddMeC was eliminated at a moderate rate relative to renal (1.51 h-1 kg-1 ) and hepatic (2.91 h-1 kg-1 ) blood flow rates ofthe rat (Gerlowski and Jain, 1983) . Renalclearance accounted for approximately half of the total clearance, with 55% of the dose recovered as unchanged AzddMeC in urine. Urinary recovery of the nucleoside was independentof dose. Renalclearance was greater than glomerular Pharmacokinetics ofAzddMeC 369 filtration rate (0.271 h-1 kg-1 ) in the rat (Patel et al., 1989) , indicating that AzddMeC underwent active tubular secretion, a feature common to nucleoside excretion (Nelson et aI., 1988) .
Non-renal clearance contributed to 45%. of the total clearance of AzddMeC. The mechanisms of the non-renal clearance of AzddMeC remain to be determined; however, glucuronidation and subsequent urinary excretion of the molecule does not appear to be a major elimination pathway for AzddMeC in the rat. Urine samples were devoid of any detectable glucuronide metabolite of the nucleoside. However, this does not rule out the possibility that AzddMeC is glucuronidated in the rat, since this metabolite may be eliminated via biliary excretion. In addition, no 3'-azido-3'-deoxythymidine (AZ1) was detected in plasma or urine, indicating that AzddMeC was not deaminated to a significant degree. Similarly, Kelley et al. (1987) have demonstrated that deamination of 2',3'_ dideoxycytidine (ddC) in mice does notoccur. However, in monkeys, AZT appears to be a major metabolite of AzddMeC (Schinazi et al., 1990) .
The disposition of AzddMeC in rats exhibited both similarities and differences with the pharmacokinetics of other nucleosides in this species. Typically, plasma nucleoside concentrations, such as with AZT (Patel et al., 1989) , ddC (Ibrahim and Boudinot, 1989a) ,carbovir (Yeom et aI., 1989) and 5'-deoxy-5-fluorouridine (Au et al., 1988) , decline in a bi-exponential fashion. AzddMeC was similar to 2' ,3' -dideoxyinosine (ddl) (Rayand Mason, 1988) in that its disposition was described by a tri-exponential decline. of AzddMeC significantly greater than the median effective concentrations for inhibiting HIV-1 were achieved and maintained for at least 3 h after doses of 50 and 100mg kg-1 .
Materials and Experimental procedures
Chemicals a. Patel et al. (1989) . b. Ibrahim and Boudinot (1989a) .
The precise mechanisms causing this three-phase decline in plasma AzddMeC concentrations have not been elucidated. However, the third phase most likely represents a slow efflux of drug from a tissue compartment. A comparison of pharmacokinetic parameters of AzddMeC, AZT and ddC in male Sprague-Dawley rats of similar age and weight is provided in Table 3 . The parameter values for AzddMeC presented are average values obtained from the 50 and 100 mg kg-1 doses. Linear pharmacokinetics were observed for AzddMeC at doses up to 100 mg kg-1 . The disposition of ddC in rats was independent of dose over the range 10 to 500mg kg-1 (Ibrahim and Boudinot, 1989a,b) . The pharmacokinetics of AZT in the rat, however, became non-linear at doses exceeding 100 mg kg-1 • Parameter values for AZT presented in Table 3 were obtained following intravenous administration of 10 and 50mg kg-1 to rats. Hence, the pharmacokinetic parameters listed in Table 3 represent the disposition characteristics of the nucleosides over a dose range where their disposition was linear.
Total, renal and non-renal clearances of AzddMeC and ddC are virtually identical. Renal clearance accounts for approximately half of the total clearance of these compounds in rats. The total clearance of AZT in rats, however, is somewhat greater than that of AzddMeC owing primarily to a higher renal clearance of AZT. In addition, the renal clearance of AZT is non-linear after doses of 100 mg kg-1 due to saturation of the active tubular secretion of the nucleoside (Patel et al., 1989) . AzddMeC is also actively secreted by the rat kidney, but to a lesser extent than AZT. Glucuronidation does not appear to be a significant route of elimination for any of these nucleoside analogues in the rat.
In summary, the effects of dose were assessed on the disposition of AzddMeC in rats. The pharmacokinetics of this nucleoside analogue were linear over the dosage range of 50 to 100mg kg-1 when administered intravenously. Clearance of AzddMeC was moderate, with renal excretion accounting for approximately half of total clearance. Metabolic deamination of AzddMeC to form AZT did not occur in the rat. Plasma drug concentrations 3' -Azido-2' ,3' -dideoxy-5-methylcytidine (AzddMeC, CS-92) and 3' -azido-2' ,3'-dideoxy-5-ethyluridine (CS-85) were synthesized in our laboratory (University of Georgia) by the method of Lin et al. (1983) . The chemical purity of the compounds, confirmed by spectral and HPLC analysis, was greater than 98%. Acetonitrile, HPLC grade, and all other chemicals, analytical grade, were obtained from J. T. Baker (Phillipsburg, NJ).I3-Glucuronidase was purchased from Sigma Chemical Company (St Louis, MO).
Experimental design
Adult male Sprague-Dawley rats weighing 250-350g were used for the study. External jugular vein cannulas were surgically implanted under light ether anaesthesia the day before the experiment. Food was withdrawn the night before the study; however, water was freely available. AzddMeC was administered in t.Ornl normal saline over 30 seconds at doses of 1'0, 50 and 100 mg kg-1 • Six rats were studied at each dose. Blood samples (0.3ml) were collected prior to and at 0. 08,0.25,0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10 and 12 h folloWing drug administration from the cannula into heparinized polypropylene microcentrifuge tubes. Blood volume was replaced with normal saline. Blood samples were immediately centrifuged and plasma was frozen at -20°C until analysis. Urine was collected at selected times for 24h after drug administration. Urine volume was measured and urine samples were frozen at -20°C until analysis.
Analytical methodology
AzddMeC concentrations in plasma and urine were determined by high-performance liquid chromatography (HPLC). Plasma (100 fLl), 50 fLl CS-85 (20fL9 mr'") as an internal standard and 100 fLl 2Mperchloric acid as a protein precipitant, were added to polypropylene micro-centrifuge tubes (400 fLl), thoroughly mixed and centrifuged at 5000 9 for 5 min. The supernatant was injected onto the HPLC (Waters Associates, Milford, MA).
Chromatography was performed on an Alltech Hypersil ODS Column (0.46 x 15em, 5 fLM particle size, Alltech Associates, Deerfield, IL)with a mobile phase consisting of 12% acetonitrile in 40mM sodium acetate, pH 7.0, at a flow rate of 2ml mln". Compounds were quantified at a UV wavelength of 283 nm with a detector range setting of 0.005 AUFS.
Urine samples were diluted 1: 100 with deionized distilled water, internal standard (20 fL9 ml-1 ) was added and 20-100 fLl of sample were injected into the HPLC. Drug concentration was multiplied by volume of urine collected to determine the amount of unchanged AzddMeC excreted.
The potential formation of AzddMeC glucuronide was ascertained in urine by hydrolysis with l3-glucuronidase (Marsh, 1986) . Urine (100fLl), 151.Li 0.12N acetic acid, 100fLi l3-glucuronidase (500 units per ml in water) and 35 fLl phosphate buffer, pH 5.8, were added to glass culture tubes, mixed and incubated with gentle shaking at 37"C in a water bath for 12 h. I3-Glucuronidasetreated urine was assayed for AzddMeC as described for urine samples. Glucuronide concentration was calculated as the difference between nucleoside concentrations measured before and after hydrolysis with l3-glucuronidase.
The AzddMeC standards ranging from 0.1 to 100 JLgml-1 were prepared in blank rat plasma and urine. Standard curve slopes and intercepts were generated by weighted (1/Y) least squares linear regression. Plasma samples with AzddMeC concentrations exceeding 100 JLg rnr' were diluted with blank rat plasma before being assayed.
Pharmacokinetics
Area/moment analysis was used to calculate the pharrnacokinetic parameters of AzddMeC. The area under the plasma concentration-time curve (AUG) and first non-normalized moment (AUMG) were determined by Lagrange polynomial interpolation and integration from time zero to the last sample time (Rocci and Jusko, 1983 ) with extrapolation to time infinity using the NONLIN least-squares terminal slope (Metzler et al., 1974) . Total clearance (CL T ) was calculated from dose/AUC, mean residence time (MRl) from AUMC/AUC and steady-state volume of distribution (Vss) from CL T x MRT. The fraction of drug excreted unchanged in urine (fe) was calculated from Au/dose, where Au is the amount of AzddMeC excreted to time infinity. Renal clearance (CLRl was calculated from fe x CL T , and non-renal clearance (CL NR ) from CLT-CL R • Half-life (t1/2) was calculated from 0.693/A, where AZ is the NONLIN least-squares terminal slope.
Statistics
Statistical analysis was performed using a one-way analysis of variance comparing the effects of dose. A probability level of less than 0.05 was considered statistically significant.
